The PMDA’s view on the limited pipeline of nephrology drugs in Japan
- 1 July 2021
- journal article
- letter
- Published by Elsevier in Kidney International
- Vol. 100 (1) , 241-242
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Innovating and invigorating the clinical trial infrastructure for glomerular diseasesKidney International, 2021
- Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory AnalysisClinical Pharmacology & Therapeutics, 2020
- International consensus definitions of clinical trial outcomes for kidney failure: 2020Kidney International, 2020
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territoriesThe Lancet, 2018